Re-exploration for retroperitoneal lymph node metastases from testis tumors

Area of Science:

• Oncology
• Surgical Oncology
• Urologic Oncology

Background:

• Prognosis is poor for patients with unresectable or recurrent retroperitoneal metastases from non-seminomatous testis tumors after initial treatment.
• Accurate assessment of residual disease is crucial for guiding further management.

Purpose of the Study:

• To evaluate the role and outcomes of re-exploration surgery in patients with persistent or recurrent retroperitoneal metastases from non-seminomatous testis tumors.
• To determine if re-exploration can lead to accurate diagnosis and modification of subsequent therapies.

Main Methods:

• Retrospective review of 11 patients with non-seminomatous testis tumors undergoing re-exploration for persistent retroperitoneal masses.
• Analysis of surgical findings, histological results, patient symptoms, and long-term outcomes.

Main Results:

• Re-exploration provided accurate diagnosis in all patients; 4 had only benign teratoma/fibrosis, avoiding further chemotherapy/radiation.
• 5 of 7 symptomatic patients improved; 3 with unresectable disease had markers placed for radiotherapy.
• Nine patients survived 6 months to 4 years, with 7 having no evidence of disease. No significant morbidity or mortality occurred.

Conclusions:

• Re-exploration is a safe and valuable procedure for selected patients with persistent retroperitoneal masses after non-seminomatous testis tumor treatment.
• Complete resection of benign masses at re-exploration indicates a good prognosis and allows for de-escalation of therapy.
• Consider re-exploration for patients with residual retroperitoneal masses post-lymphadenectomy or post-chemotherapy/radiation.